Get immediate alerts when information breaks in your shares. Declare your 1-week free trial to StreetInsider Premium here.
AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical firm centered on therapeutics for uncommon ailments, introduced a number of modifications to its government staff because the Firm celebrates one 12 months because the shut of its merger.
After a distinguished 40-year profession as an accountant and monetary government, together with over 15 profitable years with the Firm and its predecessor, Chief Monetary Officer Carl Langren has introduced his plans to retire efficient as of July 4, 2021. Mr. Langren has served as CFO of the Firm since November 2018. After his departure, Mr. Langren will proceed to function a guide to Lumos Pharma for a transitory interval to make sure a easy succession course of.
Lori Lawley, at present Senior Vice President, Finance and Company Controller, will succeed Mr. Langren as CFO efficient as of July 4, 2021. Lori Lawley is a CPA by background and has over 14 years of expertise and accounting experience in overseeing monetary operations. Ms. Lawley joined the Firm’s predecessor, NewLink Genetics, in 2015 the place she held senior roles of accelerating duty, advancing to Vice President of Finance and member of NewLink’s Workplace of the CEO in 2018. Previous to her tenure with the Firm, Ms. Lawley served as Senior Supervisor, Assurance and Advisory Enterprise Companies at Ernst & Younger. There Ms. Lawley oversaw groups by means of the planning and completion of built-in and non-integrated audits of economic statements inside each the private and non-private sectors. Ms. Lawley obtained a B.B.A. in Accounting and a Grasp in Skilled Accounting, each from the College of Texas, Purple McCombs College of Enterprise.
As well as, Lumos Pharma introduced that Eddie L. Varnado joined the Firm on April 19, 2021 as Vice President, Finance and Company Controller. Mr. Varnado brings 15 years of progressive expertise in accounting and finance roles, primarily within the biomedical and medical analysis sector. Mr. Varnado was most lately Director of Finance, Head of Scientific Finance U.S. for WuXi Scientific Growth, a world contract analysis group supporting the event cycle of prescription drugs, biopharmaceuticals and medical units. Previous to WuXi, Mr. Varnado held senior degree positions in finance at Martin Marietta, Zymergen, and Genentech the place he labored for eight years, each within the US and internationally, advancing to Senior Finance Supervisor for a number of divisions. Mr. Varnado obtained a B.S. in Enterprise Administration and Advertising and marketing from Cornell College and an M.B.A. in Finance and Funding Administration from the College of North Carolina, Kenan-Flagler College of Enterprise.
“Carl Langren and his staff introduced public firm experience to Lumos Pharma, a terrific asset throughout our merger course of and transition to a publicly traded firm,” commented Rick Hawkins, CEO, Chairman and President of Lumos Pharma. “We’re grateful for his contributions to Lumos Pharma and the development of our firm’s technique and are happy that the structural material he put in place will proceed as Lori Lawley assumes the function of CFO. I’m additionally happy to announce the addition of Eddie Varnado as VP of Finance. Our deep bench in Finance will proceed to make sure that the Firm can execute on its objectives with monetary prudence.”
“After a protracted profession culminating within the Firm’s profitable merger final 12 months, I’m happy to have the ability to retire and go away the Firm in good palms,” Carl Langren acknowledged. “I’ve labored with Lori Lawley for the final six years and am assured that the transition to her new function as CFO can be a easy one and that she is going to capably lead the Firm towards its strategic and monetary objectives.”
About Lumos Pharma
Lumos Pharma, Inc. is a medical stage biopharmaceutical firm centered on the event and commercialization of therapeutics for uncommon ailments. Lumos Pharma was based and is led by a administration staff with longstanding expertise in uncommon illness drug growth and obtained early funding from main healthcare buyers, together with Deerfield Administration, a fund managed by Blackstone Life Sciences, Roche Enterprise Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral progress hormone stimulating small molecule, at present being evaluated in a Section 2b medical trial, the OraGrowtH210 Trial, for the therapy of Pediatric Development Hormone Deficiency (PGHD). If accredited by the FDA, LUM-201 would supply an orally administered different to day by day injections that present PGHD sufferers endure for a few years of therapy. LUM-201 has obtained Orphan Drug Designation in each the US and EU. For extra data, please go to https://lumos-pharma.com/.
Cautionary Observe Relating to Ahead-Trying Statements
This press launch comprises forward-looking statements of Lumos Pharma, Inc. (the “Firm”) that contain substantial dangers and uncertainties. All such statements contained on this press launch are forward-looking statements inside the which means of The Non-public Securities Litigation Reform Act of 1995. The phrases “forecast,” “projected,” “steerage,” “upcoming,” “will,” “would,” “plan,” “intend,” “anticipate,” “approximate,” “anticipate,” “potential,” “imminent,” or the unfavorable of those phrases or different comparable expressions are meant to establish forward-looking statements, though not all forward-looking statements include these figuring out phrases. These forward-looking statements embody, amongst others, plans associated to execution of medical trials, and every other statements apart from statements of historic truth. Precise outcomes or occasions might differ materially from the plans, intentions and expectations disclosed within the forward-looking statements that the Firm makes on account of a lot of essential components, together with the consequences of pandemics or different widespread well being issues corresponding to the continued COVID-19 pandemic, the end result of our future interactions with regulatory authorities, the end result of our Section 2b OraGrowtH210 Trial for LUM-201, our means to venture future money utilization and reserves wanted for contingent future liabilities and enterprise operations, the provision of enough sources for our operations and to conduct or proceed deliberate medical growth applications, the power to acquire the required affected person enrollment for our product candidate in a well timed method, the power to efficiently develop our product candidate, the dangers related to the method of creating, acquiring regulatory approval for and commercializing drug candidates corresponding to LUM-201 which can be protected and efficient to be used as human therapeutics, the timing and skill of Lumos to boost further fairness capital as wanted and different dangers that might trigger precise outcomes to vary materially from these issues expressed in or implied by such forward-looking statements as mentioned in “Danger Components” and elsewhere in the Firm’s Annual Report on Kind 10-Ok for the 12 months ended December 31, 2020 and different reviews filed with the SEC. The forward-looking statements on this press launch symbolize the Firm’s views as of the date of this press launch. The Firm anticipates that subsequent occasions and developments will trigger their views to alter. Nevertheless, whereas it might elect to replace these forward-looking statements sooner or later sooner or later, the Firm particularly disclaims any obligation to take action. It is best to, subsequently, not depend on these forward-looking statements as representing the Firm’s views as of any date subsequent to the date of this press launch.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor Relations512-792-5454[email protected]
Supply: Lumos Pharma, Inc.